SCHEMBL443936

SCHEMBL443936

CC#CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 20/20 1.00
EGFR P00533 4/20 1.00
ITK Q08881 3/20 1.00
LCK P06239 2/20 1.00
TEC P42680 3/20 0.75
BMX P51813 3/20 0.75
TXK P42681 2/20 0.75
LYN P07948 2/20 0.75
FGFR2 P21802 2/20 0.75
FLT3 P36888 2/20 0.75
BLK P51451 2/20 0.75
RIPK2 O43353 1/20 0.75
NR1I2 O75469 1/20 0.75
SLC22A3 O75751 1/20 0.75
LATS1 O95835 1/20 0.75
NUDT14 O95848 1/20 0.75
ABL1 P00519 1/20 0.75
ERBB2 P04626 1/20 0.75
FYN P06241 1/20 0.75
PGR P06401 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL410333 1.00 BTK (1.00) BTKEGFRITKLCKTEC
SCHEMBL29663941 1.00 BTK (1.00) BTKEGFRITKLCKTEC
SCHEMBL18211764 0.95 BTK (0.91) BTKEGFRITKLCKTEC
SCHEMBL18211765 0.95 BTK (0.91) BTKEGFRITKLCKTEC
SCHEMBL18211763 0.95 BTK (0.91) BTKEGFRITKLCKTEC
SCHEMBL21330635 0.92 BTK (0.91) BTKEGFRITKLCKFLT3
SCHEMBL21330631 0.92 BTK (0.91) BTKEGFRITKLCKFLT3
SCHEMBL202258 0.90 BTK (1.00) BTKEGFRITKLCKTEC
SCHEMBL15851229 0.90 BTK (1.00) BTKEGFRITKLCKTEC
SCHEMBL23226152 0.89 BTK (0.83) BTKEGFRITKLCKTEC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150152115-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC 2015-06-04 US claimed
US-20130018060-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS, INC. (US) 2013-01-17 US claimed
US-20120277225-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS, INC. (US) 2012-11-01 US claimed
US-20120277255-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS, INC. (US) 2012-11-01 US claimed
US-20120065201-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS, INC. (US) 2012-03-15 US claimed
US-20240317756-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC (US) 2024-09-26 US disclosed
US-20240000782-A1 METHODS AND COMPOSITIONS FOR TREATING AN OPHTHALMIC CONDITION TELIOS PHARMA, INC. (US) 2024-01-04 US disclosed
US-20220213106-A1 Inhibitors of Bruton's Tyrosine Kinase PHARMACYCLICS LLC (US) 2022-07-07 US disclosed
US-20200289515-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS PHARMACYCLICS, INC. 2020-09-17 US disclosed
US-20200276199-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS PHARMACYCLICS LLC 2020-09-03 US disclosed
US-10596183-B2 Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases Zhejiang DTRM Biopharma Co. Ltd. (CN) 2020-03-24 US disclosed
US-20200055859-A1 INHIBITORS OF BRUTONS TYROSINE KINASE PHARMACYCLICS LLC (US) 2020-02-20 US disclosed
US-20110224235-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS PHARMACYCLICS, INC. (US) 2011-09-15 US disclosed
EP-2307025-A2 INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS Pharmacyclics, Inc. (US) 2011-04-13 EP disclosed
US-20100254905-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC 2010-10-07 US disclosed
US-20100254905-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC 2010-10-07 US disclosed
US-20100254905-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC 2010-10-07 US disclosed
WO-2010009342-A2 INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS PHARMACYCLICS, INC. (US) 2010-01-21 WO disclosed
EP-2139487-A2 INHIBITORS OF BRUTON'S TYROSINE KINASE Pharmacyclics, Inc. (US) 2010-01-06 EP disclosed
WO-2008121742-A2 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS, INC. (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277255-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE ABL1, BTK, ABL2 BTK 2/4885EGFR 697/4885ITK 467/4885
US-20220213106-A1 Inhibitors of Bruton's Tyrosine Kinase ABL1, BTK, ABL2 BTK 2/4885EGFR 697/4885ITK 467/4885
US-10596183-B2 Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases BTK, BCL9, BCL9L BTK 1/4885EGFR 538/4885ITK 305/4885
US-20240000782-A1 METHODS AND COMPOSITIONS FOR TREATING AN OPHTHALMIC CONDITION BTK, SYK, LCK BTK 1/4885EGFR 812/4885ITK 218/4885
US-20200289515-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS BTK, ABL1, LYN BTK 1/4885EGFR 497/4885ITK 124/4885
US-20240317756-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE ABL1, BTK, ABL2 BTK 2/4885EGFR 697/4885ITK 467/4885
US-20120277225-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE ABL1, BTK, ABL2 BTK 2/4885EGFR 697/4885ITK 467/4885
US-20100254905-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE ABL1, BTK, ABL2 BTK 2/4885EGFR 697/4885ITK 467/4885
US-20150152115-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE ABL1, BTK, ABL2 BTK 2/4885EGFR 697/4885ITK 467/4885
US-20130018060-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE ABL1, BTK, ABL2 BTK 2/4885EGFR 697/4885ITK 467/4885
US-20200055859-A1 INHIBITORS OF BRUTONS TYROSINE KINASE ABL1, BTK, ABL2 BTK 2/4885EGFR 456/4885ITK 319/4885
US-20200276199-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS BTK, ABL1, LYN BTK 1/4885EGFR 497/4885ITK 124/4885
US-20110224235-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS BTK, ABL1, LYN BTK 1/4885EGFR 497/4885ITK 124/4885
US-20120065201-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE ABL1, BTK, ABL2 BTK 2/4885EGFR 697/4885ITK 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.